LIVE TV DownloadNews18 App
News18 English
»
1-min read

Pfizer Gets Patent For Pneumonia Vaccine in India

The grant of the patent means that Indian pharmaceutical firms will not be able to make Prevenar 13 in the country.

PTI

Updated:August 22, 2017, 10:06 PM IST
facebookTwittergoogleskypewhatsapp
Pfizer Gets Patent For Pneumonia Vaccine in India
MSF Asia Regional Coordinator Prince Mathew said children everywhere have a right to be protected from pneumonia, but many governments cannot afford the prices set by Pfizer. (Photo: Reuters)
Loading...
New Delhi: Multinational drug major Pfizer Inc on Tuesday said it has been granted patent in India for its vaccine Prevenar 13, used for protection against pneumonia.

The development has, however, been decried by Medicines Sans Frontiers (MSF), an international medical humanitarian organisation saying granting patent on the vaccine could impact its availability.

The grant of the patent means that Indian pharmaceutical firms will not be able to make the vaccine.

"We are pleased to note that the validity of the Prevenar 13 patent has now been recognised by the Indian Patent Office," a Pfizer spokesperson said in a statement.

This vaccine was launched in India in 2010. In its multi-dose vial presentation, this vaccine has been included in the expansion of India's public immunisation program in select states under the GAVI funded platform, it added.

Criticising the grant of patent to Pfizer, MSF Asia Regional Coordinator Prince Mathew said: "It is unfair and unacceptable that almost a million children die each year from pneumonia, even though a life-saving vaccine is available."

Stating that the development would hit access to the vaccine, he said children everywhere have a right to be protected from pneumonia, but many governments cannot afford the prices set by Pfizer.

Pfizer, however, said it remained committed towards further enhancing access of this vaccine in India, both in the market as well as through partnership with the Government to expand introduction in the public program.

"Prevenar 13 provides the broadest serotype coverage of any pneumococcal conjugate vaccine available in the world on Tuesday," the company spokesperson said.

MSF said it had challenged Pfizer's "unmerited patent claims" in India, after the same patent was revoked by the European Patent Office (EPO) in 2016.

"The patent is also being legally challenged in South Korea and before the US Patent Trademark Appeal Board," MSF said.
Read full article
Loading...
Next Story
Next Story

Also Watch

facebookTwittergoogleskypewhatsapp
Most Active
Company Price Change %Gain
ITC 275.90 0.44
TCS 1,904.80 -3.32
Reliance 1,216.10 -0.33
Yes Bank 212.85 -0.33
Infosys 724.30 -2.26
Company Price Change %Gain
Yes Bank 212.45 -0.33
Emami 407.60 14.80
Reliance 1,216.35 -0.28
Wipro 366.05 -2.53
TCS 1,904.85 -3.39
Top Gainers
Company Price Change %Gain
Vedanta 153.10 3.45
Grasim 718.35 2.64
BPCL 335.25 2.29
JSW Steel 266.85 1.89
Zee Entertain 446.45 1.71
Company Price Change %Gain
Vedanta 153.00 3.38
ICICI Bank 343.35 1.42
ONGC 139.00 1.39
M&M 632.20 1.37
Larsen 1,255.75 1.25
Top Losers
Company Price Change %Gain
TCS 1,904.80 -3.32
Wipro 363.45 -3.23
NTPC 133.70 -2.73
IndusInd Bank 1,480.50 -2.41
Infosys 724.30 -2.26
Company Price Change %Gain
TCS 1,904.85 -3.39
NTPC 133.65 -2.34
IndusInd Bank 1,482.05 -2.30
Infosys 725.15 -2.02
Hero Motocorp 2,643.15 -1.50

Live TV

Loading...
Countdown To Elections Results
  • 01 d
  • 12 h
  • 38 m
  • 09 s
To Assembly Elections 2018 Results